Fundraising FoxCenters for Disease Control and Prevention (CDC) — 2023 Investments
7 investments dated 2023 · listed companies and verified rows first · show all
Co-investorsWellstar
Attogene manufactures rapid diagnostic assays and molecular detection kits for laboratory, environmental, and field applications, including lateral flow assays, ELISA platforms, qPCR/qLAMP systems, and nucleic acid tools.
BiotechClimate TechDeep TechDigital HealthHealthtechMedical DevicesAustin, US
Lance P. Ford(President & CEO)Joseph Krebs(Technology Officer)Brian But(Laboratory Technical Leader)
Eitr Bio develops single domain antibody-based immunotherapeutics through its Orthogonal Dual-Interacting Nanotherapeutic (ODIN) platform, including small bispecific molecules designed to penetrate solid tumors, gram-negative bacteria, and viral reservoirs in deep tissues.
BiotechDeep TechHealthtech
Luna Innovations develops fiber optics, nanomaterials, and precision assembly solutions across multiple technical domains.
Advanced ManufacturingData & InfrastructureDeep TechHardwareNew MaterialsRoanoke, US
Scott A. Graeff(Executive Officer, Director)inDavid Chanley(Director)Gary Spiegel(Director)George Gomez-Quintero(Executive Officer)Thomas Oldemeyer(Executive Officer)Brian J. Soller(Executive Officer)
Co-investorsPerot Jain
Mercato is an online grocery marketplace that connects shoppers with locally-owned, independent grocers, butchers, and bakeries for delivery or in-store pickup.
E-commerceFoodTechMarketplacesNew York, US
Robert J. Brannigan, Jr.(Executive Officer, Director, Promoter)Bobby Brannigan(Founder)in
Co-investorsBrighter CapitalFlucas VenturesGaingelsGreycroftInterlock CapitalKeshif Ventures+3 more
__Twitter.png)
Microgen develops and manufactures rapid point-of-care diagnostic tests for infectious diseases, targeting public health and clinical applications with solutions designed for speed, cost-effectiveness, and ease of use.
BiotechDeep TechHealthtechMedical Devices
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.